Related Experiment Videos
Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities
1Department of Radiology, University Hospitals K.U. Leuven, Belgium. yicheng.ni.@med.kuleuven.ac.be
Abstract:
Mangafodipir trisodium (manganese dipyridoxal diphosphate or MnDPDP) has been introduced as a hepatobiliary MR contrast agent (Teslascan). Its potential to assist in the characterisation of focal liver lesions, the diagnosis of local and global obstructive cholestasis and the evaluation of hepatic function in diffuse liver diseases has been explored in multiple pre-clinical experiments with appropriate animal models. The prompt negative contrast enhancement and delayed peritumoural rim-enhancement seen after i.v. injection of MnDPDP are 2 typical features of primary and secondary liver tumours with high malignancy, while the persistent positive enhancement is a sign of liver tumours of well preserved hepatocytic nature. Liver with local and total biliary obstruction can be visualized in MnDPDP-enhanced MR images as a region with prolonged signal enhancement. This agent could also be used to non-invasively evaluate diffuse liver diseases of different causes. In the present paper, we review the experimental data in the literature, provide some unpublished results and discuss the potential impact on the clinical use of MnDPDP in the liver. We conclude that MnDPDP is a promising MR liver contrast agent for the detection and characterisation of focal and diffuse liver diseases.
Insights
Mangafodipir trisodium (MnDPDP) shows promise as a liver MRI contrast agent. It aids in characterizing liver lesions and evaluating liver function in various diseases.
Area of Science:
- Magnetic Resonance Imaging (MRI)
- Hepatobiliary Contrast Agents
- Medical Imaging
Background:
- Mangafodipir trisodium (manganese dipyridoxal diphosphate or MnDPDP) is a hepatobiliary MRI contrast agent.
- Pre-clinical studies have explored its utility in liver disease characterization.
Purpose of the Study:
- To review experimental data and discuss the clinical potential of MnDPDP for liver imaging.
- To evaluate MnDPDP's role in characterizing focal liver lesions and diffuse liver diseases.
Main Methods:
- Review of pre-clinical experimental data from literature.
- Inclusion of unpublished experimental results.
- Discussion of MnDPDP's impact on clinical liver MRI.
Main Results:
- MnDPDP demonstrates distinct enhancement patterns for malignant liver tumors (negative contrast, rim-enhancement) and well-differentiated tumors (persistent positive enhancement).
- Obstructive cholestasis is visualized as prolonged signal enhancement in MnDPDP-enhanced MRI.
- The agent shows potential for non-invasive evaluation of diffuse liver diseases.
Conclusions:
- MnDPDP is a promising MRI contrast agent for liver imaging.
- It aids in the detection and characterization of both focal and diffuse liver diseases.
- Further clinical application of MnDPDP in liver diagnostics is anticipated.